vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and New Fortress Energy Inc. (NFE). Click either name above to swap in a different company.
New Fortress Energy Inc. is the larger business by last-quarter revenue ($326.2M vs $284.0M, roughly 1.1× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -259.7%, a 356.0% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -7.0%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -26.8%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
New Fortress Energy Inc. is a global energy infrastructure firm developing, owning and operating LNG import/export terminals, natural gas supply networks and low-carbon projects. It serves utility, industrial and public sector clients across the Americas and Caribbean, delivering affordable, lower-emission energy resources.
ACAD vs NFE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $326.2M |
| Net Profit | $273.6M | $-847.1M |
| Gross Margin | 90.8% | 35.5% |
| Operating Margin | 6.1% | -193.0% |
| Net Margin | 96.3% | -259.7% |
| Revenue YoY | 9.4% | -7.0% |
| Net Profit YoY | 90.3% | -277.4% |
| EPS (diluted) | $1.61 | $-3.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $326.2M | ||
| Q3 25 | $278.6M | $240.3M | ||
| Q2 25 | $264.6M | $228.1M | ||
| Q1 25 | $244.3M | $384.9M | ||
| Q4 24 | $259.6M | $350.7M | ||
| Q3 24 | $250.4M | $446.0M | ||
| Q2 24 | $242.0M | $291.2M | ||
| Q1 24 | $205.8M | $609.5M |
| Q4 25 | $273.6M | $-847.1M | ||
| Q3 25 | $71.8M | $-263.0M | ||
| Q2 25 | $26.7M | $-546.5M | ||
| Q1 25 | $19.0M | $-175.4M | ||
| Q4 24 | $143.7M | $-224.4M | ||
| Q3 24 | $32.8M | $9.3M | ||
| Q2 24 | $33.4M | $-88.9M | ||
| Q1 24 | $16.6M | $54.1M |
| Q4 25 | 90.8% | 35.5% | ||
| Q3 25 | 92.2% | 18.1% | ||
| Q2 25 | 92.2% | 8.4% | ||
| Q1 25 | 91.7% | 21.4% | ||
| Q4 24 | 91.6% | 17.6% | ||
| Q3 24 | 92.5% | 27.1% | ||
| Q2 24 | 92.5% | 23.8% | ||
| Q1 24 | 88.8% | 62.4% |
| Q4 25 | 6.1% | -193.0% | ||
| Q3 25 | 12.8% | -37.4% | ||
| Q2 25 | 12.2% | -170.3% | ||
| Q1 25 | 7.9% | -3.3% | ||
| Q4 24 | 59.1% | 65.0% | ||
| Q3 24 | 12.6% | 17.8% | ||
| Q2 24 | 12.6% | 12.3% | ||
| Q1 24 | 7.4% | 30.4% |
| Q4 25 | 96.3% | -259.7% | ||
| Q3 25 | 25.8% | -109.4% | ||
| Q2 25 | 10.1% | -239.6% | ||
| Q1 25 | 7.8% | -45.6% | ||
| Q4 24 | 55.4% | -64.0% | ||
| Q3 24 | 13.1% | 2.1% | ||
| Q2 24 | 13.8% | -30.5% | ||
| Q1 24 | 8.0% | 8.9% |
| Q4 25 | $1.61 | $-3.03 | ||
| Q3 25 | $0.42 | $-0.96 | ||
| Q2 25 | $0.16 | $-1.99 | ||
| Q1 25 | $0.11 | $-0.65 | ||
| Q4 24 | $0.86 | $-1.10 | ||
| Q3 24 | $0.20 | $0.03 | ||
| Q2 24 | $0.20 | $-0.42 | ||
| Q1 24 | $0.10 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $226.5M |
| Total DebtLower is stronger | — | $8.2B |
| Stockholders' EquityBook value | $1.2B | $182.6M |
| Total Assets | $1.6B | $10.6B |
| Debt / EquityLower = less leverage | — | 44.78× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $226.5M | ||
| Q3 25 | $258.0M | $145.2M | ||
| Q2 25 | $253.6M | $551.1M | ||
| Q1 25 | $217.7M | $447.9M | ||
| Q4 24 | $319.6M | $492.9M | ||
| Q3 24 | $155.1M | $90.8M | ||
| Q2 24 | $177.1M | $133.0M | ||
| Q1 24 | $204.7M | $143.5M |
| Q4 25 | — | $8.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $182.6M | ||
| Q3 25 | $917.3M | $1.1B | ||
| Q2 25 | $822.4M | $1.3B | ||
| Q1 25 | $765.2M | $1.8B | ||
| Q4 24 | $732.8M | $1.9B | ||
| Q3 24 | $577.2M | $1.6B | ||
| Q2 24 | $516.7M | $1.6B | ||
| Q1 24 | $464.0M | $1.7B |
| Q4 25 | $1.6B | $10.6B | ||
| Q3 25 | $1.3B | $12.0B | ||
| Q2 25 | $1.2B | $12.0B | ||
| Q1 25 | $1.1B | $13.1B | ||
| Q4 24 | $1.2B | $12.9B | ||
| Q3 24 | $976.9M | $12.0B | ||
| Q2 24 | $914.1M | $11.4B | ||
| Q1 24 | $855.1M | $10.9B |
| Q4 25 | — | 44.78× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.74× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $-76.2M |
| Free Cash FlowOCF − Capex | — | $-134.8M |
| FCF MarginFCF / Revenue | — | -41.3% |
| Capex IntensityCapex / Revenue | — | 18.0% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $-76.2M | ||
| Q3 25 | $74.3M | $-171.0M | ||
| Q2 25 | $64.0M | $-329.0M | ||
| Q1 25 | $20.3M | $-7.2M | ||
| Q4 24 | $40.4M | $445.3M | ||
| Q3 24 | $63.2M | $-20.0M | ||
| Q2 24 | $25.0M | $113.9M | ||
| Q1 24 | $29.1M | $63.0M |
| Q4 25 | — | $-134.8M | ||
| Q3 25 | $73.9M | $-231.6M | ||
| Q2 25 | — | $-726.7M | ||
| Q1 25 | — | $-262.3M | ||
| Q4 24 | — | $-210.3M | ||
| Q3 24 | $63.2M | $-367.0M | ||
| Q2 24 | — | $-493.2M | ||
| Q1 24 | — | $-457.9M |
| Q4 25 | — | -41.3% | ||
| Q3 25 | 26.5% | -96.4% | ||
| Q2 25 | — | -318.6% | ||
| Q1 25 | — | -68.2% | ||
| Q4 24 | — | -60.0% | ||
| Q3 24 | 25.2% | -82.3% | ||
| Q2 24 | — | -169.3% | ||
| Q1 24 | — | -75.1% |
| Q4 25 | — | 18.0% | ||
| Q3 25 | 0.1% | 25.2% | ||
| Q2 25 | — | 174.4% | ||
| Q1 25 | — | 66.3% | ||
| Q4 24 | — | 187.0% | ||
| Q3 24 | 0.0% | 77.8% | ||
| Q2 24 | — | 208.4% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | -2.15× | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | 1.16× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
NFE
Segment breakdown not available.
